No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.

Contact us

Thank you for your interest. Shire US Inc. welcomes your comments and questions.

Health care professionals

Clinical inquiries: US health care professionals may call Shire Medical Information toll-free at 1-800-828-2088 or send an e-mail to medinfoglobal@shire.com.

Shire US Inc.
300 Shire Way
Lexington, MA 02421

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.